Holen Sie sich die Stockscreener-App
3.01
1.69%
0.05
Handel nachbörslich:
3.03
0.02
+0.66%
Schlusskurs vom Vortag:
$2.96
Offen:
$3.03
24-Stunden-Volumen:
21.66M
Relative Volume:
1.10
Marktkapitalisierung:
$1.60B
Einnahmen:
$66.41M
Nettoeinkommen (Verlust:
$-559.78M
KGV:
-2.5037
EPS:
-1.2022
Netto-Cashflow:
$-328.09M
1W Leistung:
+4.15%
1M Leistung:
-14.49%
6M Leistung:
-34.57%
1J Leistung:
-53.62%
1-Tages-Spanne:
$2.99
$3.13
1-Wochen-Bereich:
$2.90
$3.13
52-Wochen-Spanne:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.01 | 1.57B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades - Stock Titan
RXRX|Recursion Pharmaceuticals Inc|Price:3.030| - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Cash Flow - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
TradingKey - TradingKey
Recursion Pharmaceuticals Stock (RXRX) Opinions on Trading Ranges and Biotech Prospects - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Recursion Pharmaceuticals Inc (RXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Recursion Pharmaceuticals, Inc (RXRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Recursion Pharmaceuticals Inc (RXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Institutional Confidence - TradingKey
RXRX|Recursion Pharmaceuticals Inc|Price:2.995|Chg%:-0.015 - TradingKey
Recursion Pharmaceuticals, Inc. (RXRX) Options Chain - Yahoo! Finance Canada
Recursion Pharmaceuticals Inc (RXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Recursion Pharmaceuticals (RXRX) Proxy filing Summary - Quartr
Recursion Pharmaceuticals (RXRX) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary - Quartr
RXRX|Recursion Pharmaceuticals Inc|Price:3.030|Chg%:+0.020 - TradingKey
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals Stock Short Interest Falls to 34.41% - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 150% Upside Potential in Biotechnology - DirectorsTalk Interviews
RXRX: Recursion Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Form 144 RECURSION PHARMACEUTICALS For: 17 July By Investing.com - Investing.com Canada
Form 144 RECURSION PHARMACEUTICALS For: 16 July By Investing.com - Investing.com Nigeria
RXRX Stock Slips Onto Watchlists After Insider Form 144 - timothysykes.com
RXRX Stock Under Pressure As Insider Signals Share Sale - StocksToTrade
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today - Yahoo Finance
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? - The Globe and Mail
Form 144 RECURSION PHARMACEUTICALS For: 13 July By Investing.com - Investing.com Australia
Price to sales forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Price to book forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Enterprise value to revenue forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Price to earnings forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced? - Sahm
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects - Moomoo
Form 144 RECURSION PHARMACEUTICALS For: 10 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary - Quartr
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Insider Sell: Blake Borgeson Sells 40,000 Shares of Recursion Ph - GuruFocus
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals director Borgeson sells $158,500 stock - Investing.com
Recursion Pharmaceuticals (RXRX) director sells 40,000 shares in 10b5-1 trade - Stock Titan
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):